
|Videos|April 24, 2017
Biosimilars in Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses the potential impact of biosimilars on specialty pharmacy.
Advertisement
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses the potential impact of biosimilars on specialty pharmacy.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Myelofibrosis and the Central Role of JAK Pathway Dysregulation
2
Clinical Manifestations and Prognostic Impact of Anemia in Myelofibrosis
3
Enfortumab Vedotin Plus Pembrolizumab Shows Promise as a Platinum-Free Option in Earlier Bladder Cancer
4
Advancing the Role of Pharmacy Technicians in Hazardous Drug Compounding
5









































































































































































































